Want to see CH:CMHC full AI Analyst Report?
Top Page
COSMO Pharmaceuticals N.V.
(CMHC)
Select Model
Select Model
Rating:53Neutral
Price Target:
CHF58.00
▲(2.29% Upside)
Action:Reiterated
Date:07/25/26
The score is held back primarily by unstable operating performance and a swing to negative operating/free cash flow in the latest year, alongside a bearish technical trend (price below key moving averages with negative MACD). A strong, conservative balance sheet and a moderate dividend yield partially offset these risks but do not fully outweigh the recent profitability and cash-flow deterioration.
Positive Factors
Conservative balance sheet
Minimal leverage and substantial equity provide financial flexibility to fund product development, partnerships, and commercialization through volatile operating periods without relying heavily on external borrowing.
Negative Factors
Sharp revenue contraction
Such a large year-over-year decline weakens revenue visibility and suggests that product, licensing, or milestone contributions may be uneven, making the current operating run-rate difficult to extrapolate.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Minimal leverage and substantial equity provide financial flexibility to fund product development, partnerships, and commercialization through volatile operating periods without relying heavily on external borrowing.
Read all positive factors
COSMO Pharmaceuticals N.V. (CMHC) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF961.44M
Dividend Yield3.45%
Average Volume (3M)19.52K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-44.72%
EPS Growth-110.73%
CountryCH
Employees325
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF115.00Price Target Upside102.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.12
Revenue Forecast (FY)CHF106.44M
COSMO Pharmaceuticals N.V. Business Overview & Revenue Model
Company Description
Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Elevie...
How the Company Makes Money
Cosmo generates revenue primarily through (1) sales of its own commercialized products and (2) partnering/licensing arrangements in which other pharmaceutical companies commercialize Cosmo-originated products in specific territories or indications...
COSMO Pharmaceuticals N.V. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.69M | 104.85M | 266.79M | 92.78M | 102.09M | 65.07M |
| Gross Profit | 46.74M | 48.78M | 246.92M | 53.44M | 83.33M | 49.93M |
| EBITDA | -636.78K | 2.36M | 165.71M | 19.70M | 46.74M | 17.81M |
| Net Income | -6.35M | -3.63M | 133.24M | -4.93M | 17.23M | 21.67M |
Balance Sheet | ||||||
| Total Assets | 695.64M | 612.16M | 646.77M | 553.98M | 759.59M | 805.56M |
| Cash, Cash Equivalents and Short-Term Investments | 195.28M | 122.66M | 142.96M | 50.27M | 240.95M | 222.21M |
| Total Debt | 4.33M | 4.26M | 2.20M | 1.84M | 173.60M | 169.92M |
| Total Liabilities | 121.91M | 123.36M | 141.68M | 124.94M | 295.80M | 292.88M |
| Stockholders Equity | 567.02M | 481.92M | 498.33M | 422.16M | 456.93M | 505.28M |
Cash Flow | ||||||
| Free Cash Flow | -23.82M | -15.85M | 156.76M | 18.31M | 25.92M | 4.11M |
| Operating Cash Flow | -20.08M | -11.62M | 162.41M | 22.71M | 33.23M | 12.61M |
| Investing Cash Flow | -95.36M | 49.85M | -128.88M | 42.30M | 1.69M | 24.86M |
| Financing Cash Flow | 94.90M | -24.61M | -40.22M | -211.27M | -46.13M | -27.25M |
COSMO Pharmaceuticals N.V. Technical Analysis
Negative
56.70
Price Trends
62.82
Negative
71.53
Negative
82.95
Negative
Market Momentum
-1.75
Negative
36.74
Neutral
13.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:CMHC, the sentiment is Negative. The current price of 56.7 is below the 20-day moving average (MA) of 59.07, below the 50-day MA of 62.82, and below the 200-day MA of 82.95, indicating a bearish trend. The MACD of -1.75 indicates Negative momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 13.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:CMHC.
COSMO Pharmaceuticals N.V. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | CHF803.59M | 15.14 | ― | ― | 4.74% | -28.96% | |
66 Neutral | CHF4.18B | 26.44 | ― | 2.88% | 6.48% | -17.25% | |
62 Neutral | CHF31.04B | 56.36 | 10.09% | 1.26% | 0.81% | 165.32% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | CHF961.44M | -158.93 | 11.46% | 3.11% | -44.72% | -110.73% | |
32 Underperform | CHF1.52B | -4.07 | ― | ― | -8.06% | -87.00% |
* General Sector Average
CH:CMHC
COSMO Pharmaceuticals N.V.
56.60
-7.37
-11.52%
CH:BSLN
Basilea Pharmaceutica
64.50
17.65
37.67%
CH:IDIA
Idorsia Ltd
5.34
2.61
96.14%
CH:SDZ
Sandoz Group Ltd
68.90
19.30
38.92%
CH:GALE
Galenica AG
84.35
0.78
0.94%
CH:BIOV
BioVersys AG
26.80
-5.10
-15.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.